MX2023002233A - Compuestos fosfolipidos y usos de estos. - Google Patents

Compuestos fosfolipidos y usos de estos.

Info

Publication number
MX2023002233A
MX2023002233A MX2023002233A MX2023002233A MX2023002233A MX 2023002233 A MX2023002233 A MX 2023002233A MX 2023002233 A MX2023002233 A MX 2023002233A MX 2023002233 A MX2023002233 A MX 2023002233A MX 2023002233 A MX2023002233 A MX 2023002233A
Authority
MX
Mexico
Prior art keywords
compounds
phospholipid compounds
phospholipid
singly
formula
Prior art date
Application number
MX2023002233A
Other languages
English (en)
Inventor
Peiyuan Wang
Scott E Lazerwith
Devan Naduthambi
Jonathan William Medley
Philip A Morganelli
Thomas P Stratton
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of MX2023002233A publication Critical patent/MX2023002233A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Abstract

Se describen compuestos y métodos para usar los compuestos, solos o en combinación con agentes adicionales, y composiciones farmacéuticas de los compuestos para el tratamiento de infecciones virales (Fórmula (I)). (ver Fórmula).
MX2023002233A 2020-08-24 2021-08-23 Compuestos fosfolipidos y usos de estos. MX2023002233A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063069449P 2020-08-24 2020-08-24
US202063092386P 2020-10-15 2020-10-15
US202163151509P 2021-02-19 2021-02-19
PCT/US2021/047145 WO2022046631A1 (en) 2020-08-24 2021-08-23 Phospholipid compounds and uses thereof

Publications (1)

Publication Number Publication Date
MX2023002233A true MX2023002233A (es) 2023-03-15

Family

ID=77802251

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002233A MX2023002233A (es) 2020-08-24 2021-08-23 Compuestos fosfolipidos y usos de estos.

Country Status (16)

Country Link
US (3) US11773122B2 (es)
EP (1) EP4200301A1 (es)
JP (1) JP2023538442A (es)
KR (1) KR20230057419A (es)
CN (1) CN116323630A (es)
AU (2) AU2021330835B2 (es)
BR (1) BR112023002951A2 (es)
CA (1) CA3188373A1 (es)
CL (1) CL2023000524A1 (es)
CO (1) CO2023001953A2 (es)
CR (1) CR20230100A (es)
DO (1) DOP2023000037A (es)
IL (1) IL300412A (es)
MX (1) MX2023002233A (es)
TW (2) TW202337471A (es)
WO (1) WO2022046631A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4200301A1 (en) 2020-08-24 2023-06-28 Gilead Sciences, Inc. Phospholipid compounds and uses thereof
TWI811812B (zh) 2020-10-16 2023-08-11 美商基利科學股份有限公司 磷脂化合物及其用途
TW202317144A (zh) 2021-06-14 2023-05-01 美商維納拓爾斯製藥公司 口服生物可利用的核苷類似物
AU2022328698A1 (en) * 2021-08-18 2024-02-01 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
CN115251042B (zh) * 2022-09-08 2023-06-02 安徽科技学院 一种家禽精液稀释缓冲液及其制备和家禽精液冷存方法

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
DE3778626D1 (de) 1986-09-27 1992-06-04 Toyo Jozo Kk Nukleosid-phospholipid-konjugat.
US7517858B1 (en) 1995-06-07 2009-04-14 The Regents Of The University Of California Prodrugs of pharmaceuticals with improved bioavailability
AUPQ105499A0 (en) 1999-06-18 1999-07-08 Biota Scientific Management Pty Ltd Antiviral agents
CA2747954C (en) 1999-12-03 2014-02-25 The Regents Of The University Of California Phosphonate compounds
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EA005890B1 (ru) 2000-05-26 2005-06-30 Айденикс (Кайман) Лимитед СПОСОБЫ ЛЕЧЕНИЯ ИНФЕКЦИЙ, ВЫЗЫВАЕМЫХ ВИРУСОМ ГЕПАТИТА ДЕЛЬТА, С ИСПОЛЬЗОВАНИЕМ β-L-2'-ДЕЗОКСИНУКЛЕОЗИДОВ
AUPR213700A0 (en) 2000-12-18 2001-01-25 Biota Scientific Management Pty Ltd Antiviral agents
WO2004112687A2 (en) 2003-06-26 2004-12-29 Biotron Limited Antiviral acylguanidine compounds and methods
EP1831235B1 (en) 2004-12-16 2013-02-20 The Regents of The University of California Lung-targeted drugs
US20090156545A1 (en) 2005-04-01 2009-06-18 Hostetler Karl Y Substituted Phosphate Esters of Nucleoside Phosphonates
DK1902017T3 (da) 2005-06-24 2014-06-30 Biotron Ltd Antivirale acylguanidinforbindelser
ES2563477T3 (es) 2007-08-03 2016-03-15 Biotron Limited Composiciones antivirales para tratar la hepatitis C a base de 5-(1-metilpirazol-4-il)2-naftoilguanidina y 2'-C-metiladenosina o 2'-C-metilcitidina
EP2313102A2 (en) 2008-07-03 2011-04-27 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
WO2010039548A2 (en) 2008-09-23 2010-04-08 Alnylam Pharmaceuticals, Inc. Chemical modifications of monomers and oligonucleotides with cycloaddition
ES2534044T3 (es) 2008-11-06 2015-04-16 Vascular Biogenics Ltd. Compuestos de lípidos oxidados y usos de los mismos
CA2778175A1 (en) 2009-11-11 2011-05-19 Yoshihiro Horiuchi 8-azabicyclo[3.2.1]octane-8-carboxamide derivative
WO2011100131A2 (en) 2010-01-28 2011-08-18 Alnylam Pharmacuticals, Inc. Monomers and oligonucleotides comprising cycloaddition adduct(s)
TW201201815A (en) 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
SG10201610936RA (en) 2011-12-22 2017-02-27 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
PE20150776A1 (es) 2012-09-10 2015-05-21 Hoffmann La Roche 6-aminoacido-heteroarildihidropirimidinas para el tratamiento y profilaxis de la infeccion del virus de la hepatitis b
EP3421482A1 (en) 2012-12-21 2019-01-02 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
CN108619161A (zh) 2013-03-15 2018-10-09 加利福尼亚大学董事会 无环核苷膦酸二酯
TW201542578A (zh) 2013-06-26 2015-11-16 Alios Biopharma Inc 經取代之核苷、核苷酸及其類似物
BR112016005507B1 (pt) 2013-09-11 2023-02-07 Centre National De La Recherche Scientifique (Cnrs) Uso de um agonista do receptor farnesoide x (fxr)
TW201524990A (zh) 2013-10-11 2015-07-01 Alios Biopharma Inc 經取代之核苷、核苷酸及其類似物
CN105899508B (zh) 2014-01-30 2017-07-04 豪夫迈·罗氏有限公司 用于治疗和预防乙型肝炎病毒感染的新型二氢喹嗪酮类化合物
NZ721520A (en) 2014-03-07 2023-03-31 Hoffmann La Roche Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
CN106459032B (zh) 2014-05-13 2019-04-05 豪夫迈·罗氏有限公司 治疗和预防乙型肝炎病毒感染的新的二氢喹嗪酮类
EP3160475B1 (en) 2014-06-24 2024-01-03 Janssen Pharmaceuticals, Inc. Substituted nucleosides and nucleotides to treat filoviridae infections
DK3160476T3 (da) 2014-06-24 2020-12-21 Janssen Biopharma Inc Substituerede nukleosider, nukleotider og analoger dertil til anvendelse til behandling af virusinfektioner
WO2016012470A1 (en) 2014-07-25 2016-01-28 F. Hoffmann-La Roche Ag New amorphous and crystalline forms of (3s)-4-[[(4r)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-1, 4-dihydropyrimidin-6-yl]methyl]morpholine-3-carboxylic acid
EP3180319B1 (en) 2014-08-14 2018-10-03 F.Hoffmann-La Roche Ag Novel pyridazones and triazinones for the treatment and prophylaxis of hepatitis b virus infection
US9637485B2 (en) 2014-11-03 2017-05-02 Hoffmann-La Roche Inc. 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection
US9676793B2 (en) 2014-12-23 2017-06-13 Hoffmann-Laroche Inc. Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same
WO2016102438A1 (en) 2014-12-23 2016-06-30 F. Hoffmann-La Roche Ag Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidine analogues
EP3240537B1 (en) 2014-12-30 2020-09-09 F. Hoffmann-La Roche AG Novel tetrahydropyridopyrimidines and tetrahydropyridopyridines for the treatment and prophylaxis of hepatitis b virus infection
EP3240913A1 (en) 2014-12-31 2017-11-08 F. Hoffmann-La Roche AG A novel high-throughput method for quantification of hbv cccdna from cell lysate by real-time pcr
MA41338B1 (fr) 2015-01-16 2019-07-31 Hoffmann La Roche Composés de pyrazine pour le traitement de maladies infectieuses
EP3250685A1 (en) 2015-01-27 2017-12-06 F. Hoffmann-La Roche AG Recombinant hbv cccdna, the method to generate thereof and the use thereof
CN107207505B (zh) 2015-02-11 2018-12-14 豪夫迈·罗氏有限公司 治疗和预防乙型肝炎病毒感染的 2-氧代-6,7-二氢苯并[a]喹嗪-3-甲酸衍生物
WO2017165489A1 (en) 2016-03-23 2017-09-28 Emory University Antiviral agents for treating zika and dengue virus infections
KR102607599B1 (ko) 2017-02-08 2023-11-28 바이오트론 리미티드 인플루엔자의 치료 방법
KR102460968B1 (ko) * 2017-03-14 2022-11-01 길리애드 사이언시즈, 인코포레이티드 고양이 코로나바이러스 감염의 치료 방법
WO2019027905A1 (en) 2017-07-31 2019-02-07 January Therapeutics, Inc. ORGANOPHOSPHATE DERIVATIVES
CR20200126A (es) 2017-09-18 2020-07-11 Janssen Biopharma Inc Nucleósidos sustituidos, nucleótidos y análogos de estos
CA3087192A1 (en) 2017-12-27 2019-07-04 Raymond F. Schinazi Combined modalities for nucleosides and/or nadph oxidase (nox) inhibitors as myeloid-specific antiviral agents
AU2019227986A1 (en) 2018-03-02 2020-10-08 January Therapeutics, Inc. Nanoparticle compositions
TWI791193B (zh) * 2020-02-18 2023-02-01 美商基利科學股份有限公司 抗病毒化合物
WO2022020793A1 (en) 2020-07-24 2022-01-27 The Regents Of The University Of California Antiviral prodrugs, pharmaceutical formulations, and methods
EP4200301A1 (en) 2020-08-24 2023-06-28 Gilead Sciences, Inc. Phospholipid compounds and uses thereof
TWI811812B (zh) 2020-10-16 2023-08-11 美商基利科學股份有限公司 磷脂化合物及其用途
TW202317144A (zh) 2021-06-14 2023-05-01 美商維納拓爾斯製藥公司 口服生物可利用的核苷類似物
AU2022328698A1 (en) * 2021-08-18 2024-02-01 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same

Also Published As

Publication number Publication date
US20240025932A1 (en) 2024-01-25
CA3188373A1 (en) 2022-03-03
US11773122B2 (en) 2023-10-03
TWI807399B (zh) 2023-07-01
CR20230100A (es) 2023-04-28
CN116323630A (zh) 2023-06-23
EP4200301A1 (en) 2023-06-28
CO2023001953A2 (es) 2023-03-17
WO2022046631A1 (en) 2022-03-03
JP2023538442A (ja) 2023-09-07
TW202337471A (zh) 2023-10-01
AU2021330835B2 (en) 2023-12-14
CL2023000524A1 (es) 2023-09-29
TW202222323A (zh) 2022-06-16
US20230250117A1 (en) 2023-08-10
BR112023002951A2 (pt) 2023-03-21
DOP2023000037A (es) 2023-07-09
US20220081455A1 (en) 2022-03-17
AU2024201573A1 (en) 2024-04-04
IL300412A (en) 2023-04-01
AU2021330835A1 (en) 2023-03-30
KR20230057419A (ko) 2023-04-28

Similar Documents

Publication Publication Date Title
MX2023002195A (es) Compuestos y metodos para el tratamiento de infecciones virales.
CR20230100A (es) Compuestos fosfolípidos y usos de los mismos
CR20220675A (es) Análogos de nucleósido de 1´- ciano y usos de los mismos
MX2021009246A (es) Inmunomoduladores, composiciones y metodos de los mismos.
MX2022015272A (es) Inhibidores de la proteina kras g12c y usos de estos.
MX2023004923A (es) Compuestos heterociclicos como inmunomoduladores.
CR20220303A (es) Compuestos moduladores de la diacilglicerol quinasa
NO20064547L (no) Fremgangsmater for behandling av HIV infeksjon
CR20230164A (es) Compuestos fosfolípidos y usos de estos
MX348481B (es) Productos quimicos, composiciones y metodos para tratamiento y prevencion de infecciones de virus orthopox y enfermedades asociadas.
MX2009005881A (es) Derivados de 2-(piperidin-4-il)-4-fenoxi o fenilamino-pirimidina como inhibidores de la transcriptasa inversa no nucleosida.
WO2020083971A3 (en) New anthelmintic compounds
MX2008008556A (es) Derivados de triterpenoquinonas y triterpenofenoles y su aplicacion para el tratamiento de tumores y enfermedades parasitarias.
EP4342473A3 (en) Compounds useful in hiv therapy
AU2020231934A8 (en) Compounds useful in HIV therapy
MX2022001004A (es) Inhibidores de enzimas.
CR20220014A (es) Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos
MX2021001612A (es) Compuestos utiles en terapia del vih.
BR112018015629A2 (pt) ?composto, composição, método para tratar um mamífero infectado com o vírus hiv, e, proteína mutante tripla?
PH12021551058A1 (en) Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof
MX2022001261A (es) Derivados de dihidropirimidina y usos de los mismos en el tratamiento de infeccion por vhb o de enfermedades inducidas por vhb.
TW202417008A (zh) 1'-氰基核苷類似物及其用途
MX2023005913A (es) Derivados de bencenosulfonamida y usos de los mismos.
WO2023003882A3 (en) Compounds having selective inactivation activity
PH12020550059A1 (en) Novel ophthalmic composition and methods of use